Extended Data Fig. 3: Change from baseline in total RQLQ score and individual domains scores at 2-week (a) and 4-week treatment (b).
From: Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial
Least-squares mean changes are shown for 50 patients in the stapokibart group and 58 in the placebo group; error bars indicate standard errors. Data are shown as differences in median value (95% confidence interval). Scatter points indicate change from baseline value for individual patient. The total RQLQ is used to assess the quality of life status in adult patients with rhinoconjunctivitis; total scores range from 0 to 6, with lower scores indicating a higher quality of life. The individual domain ranges from 0 (no trouble) to 6 points (extreme trouble). Data was analyzed using the Analysis of Covariance (ANCOVA) model, with the baseline RQLQ score, study site, and treatment group as covariates. Missing data for RQLQ was imputed by last observation carried forward method. Changes from baseline in total RQLQ score at week 2 and week 4 were multiplicity-tested efficacy outcomes with type I error controlled by step-down test procedures. P values for individual domains scores were two-sided and nominal, without adjustments for multiple comparisons. RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire.
